Not so fast for AbbVie in SEZ6
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
China’s latest Car-T bets revealed
First-in-human listings bring a bispecific and yet another in vivo Car-T.
Regeneron bets big on Lynozyfic
The company is starting four new pivotal trials this year.
A first for CCR8
Cafelkibart’s entry into phase 3 is of note to Coherus.
Sanofi steps back from radioconjugates
The company quietly deprioritises AlphaMedix.
Revolution adds to its KRAS ambitions
RMC-5127 becomes the company’s fourth clinical project.
Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
The ranks of Rybrevant challengers swell
The line-up is revealed to include Merck & Co and J&J itself.
The month ahead: February’s upcoming events
Tecvayli and Hernexeos might get speedy approval decisions.
